{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:29:46Z","timestamp":1715992186891},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2011,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD19 is an attractive therapeutic target for treating human B\u2010cell tumors. In our study, chimeric (c) divalent (cHD37) and tetravalent (cHD37\u2010DcVV) anti\u2010CD19 monoclonal antibodies (MAbs) were constructed, expressed and evaluated for their binding to human 19\u2010positive (CD19<jats:sup>+<\/jats:sup>) tumor cell lines. They were also tested for proapoptotic activity and the ability to mediate effector functions. The antitumor activity of these MAbs was further tested in mice xenografted with the CD19<jats:sup>+<\/jats:sup> Burkitt's lymphoma cell line, Daudi or the pre\u2010B acute lymphoblastic leukemia (ALL) cell line, NALM\u20106. The cHD37 and cHD37\u2010DcVV MAbs exhibited specific binding and comparable proapoptotic activity on CD19<jats:sup>+<\/jats:sup> tumor cell lines <jats:italic>in vitro<\/jats:italic>. In addition, the cHD37 and cHD37\u2010DcVV MAbs were similar in their ability to mediate antibody\u2010dependent cell\u2010mediated phagocytosis (ADCP). However, the tetravalent cHD37\u2010DcVV MAb bound more avidly, had a slower dissociation rate, and did not internalize as well. It also had enhanced antibody\u2010dependent cellular cytotoxicity (ADCC) with human but not <jats:styled-content>murine<\/jats:styled-content> effector cells. The cHD37 and cHD37\u2010DcVV MAbs exhibited comparable affinity for the human neonatal Fc receptor (FcRn) and similar pharmacokinetics (PKs) in mice. Moreover, all the HD37 constructs were similar in extending the survival of mice xenografted with Daudi or NALM\u20106 tumor cells. Therefore, the cHD37 and cHD37\u2010DcVV MAbs have potent antitumor activity and should be further developed for use in humans. Although not evident in mice, due to its increased ability to mediate ADCC with human but not mouse effector cells, the cHD37\u2010DcVV MAb should have superior therapeutic efficacy in humans.<\/jats:p>","DOI":"10.1002\/ijc.25695","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T14:49:09Z","timestamp":1285685349000},"page":"497-506","source":"Crossref","is-referenced-by-count":9,"title":["Chimeric, divalent and tetravalent anti\u2010CD19 monoclonal antibodies with potent <i>in vitro<\/i> and <i>in vivo<\/i> antitumor activity against human B\u2010cell lymphoma and pre\u2010B acute lymphoblastic leukemia cell lines"],"prefix":"10.1002","volume":"129","author":[{"given":"Xiao\u2010Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurentiu M.","family":"Pop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iliodora V.","family":"Pop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen S.","family":"Vitetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2744"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00007.x"},{"key":"e_1_2_6_4_2","first-page":"611","article-title":"Therapy of B\u2010cell lymphoma with anti\u2010CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis TA","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03843.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.143.2.712","article-title":"Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily","volume":"143","author":"Tedder TF","year":"1989","journal-title":"J Immunol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830251040"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7684160"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"21172","DOI":"10.1016\/S0021-9258(19)36907-8","article-title":"Signal transduction through the CD19 receptor during discrete developmental stages of human B\u2010cell ontogeny","volume":"268","author":"Uckun FM","year":"1993","journal-title":"J Biol Chem"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)31664-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1547"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109769"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.13.13"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell\u2010associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson KC","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505539102"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/108497804773391630"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-182048"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179143"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600821989"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.06.027"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","article-title":"Anti\u2010CD19 inhibits the growth of human B\u2010cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest","volume":"83","author":"Ghetie MA","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4255"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1188.bloodjournal8841188"},{"key":"e_1_2_6_26_2","first-page":"1302","article-title":"A phase I study of combination therapy with immunotoxins IgG\u2010HD37\u2010deglycosylated ricin A chain (dgA) and IgG\u2010RFB4\u2010dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma","volume":"6","author":"Messmann RA","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.07.002"},{"key":"e_1_2_6_28_2","first-page":"5301","article-title":"Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy","volume":"54","author":"Vitetta ES","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.14.7509"},{"key":"e_1_2_6_30_2","first-page":"2560","article-title":"Monoclonal antibody homodimers: enhanced antitumor activity in nude mice","volume":"53","author":"Wolff EA","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1154-03"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.9.4854"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.11.022"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(92)90092-8"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1345"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000210079.52554.c3"},{"key":"e_1_2_6_37_2","first-page":"835","article-title":"The fate of antibodies bound to the surface of tumor cells in vitro","volume":"52","author":"Kyriakos RJ","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90107-M"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229039"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60671-9"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(04)82004-2"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80430-4"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400476"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death","volume":"116","author":"Danial NN","year":"2003","journal-title":"Cell"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E09-07-0649"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.12.1551"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:25:2:097"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00230-1"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.003"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.11.010"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.25695","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.25695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:32:41Z","timestamp":1697470361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.25695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7,15]]}},"alternative-id":["10.1002\/ijc.25695"],"URL":"https:\/\/doi.org\/10.1002\/ijc.25695","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}